Introduction
Acutely ill hospitalized medical patients are at significant risk of developing venous thromboembolic (VTE) complications, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). 1, 2 It has been calculated that 70% to 80% of fatal PE occurs in medical rather than surgical patients, 3 and that rates of DVT in medical inpatients range from 10% to 40%, depending on the medical condition of the patient and the presence of concomitant thrombotic risk factors. 1 Indeed, hospitalization for an acute medical illness is independently associated with an eightfold increase in the risk of a VTE event. 4 Moreover, the economic burden of VTE, VTE recurrence, and its long-term complications is sizeable. One study estimated that the total annual cost of VTE events (excluding physician costs) in the United States was US$1.5 billion. 5 Another study, investigating the cost of DVT treatment, found that hospitalization facility costs accounted for 70% of the total hospitalization expenditure, with hospitalization professional costs (7.6%) and outpatient procedures (6.9%) being the next most expensive components. 6 Prophylaxis of VTE should be used to help reduce the burden of VTE and its long-term complications. Prophylaxis of VTE with either a low-dose unfractionated heparin (UFH) or a low-molecularweight heparin (LMWH) reduces the incidence of VTE in medical patients and is well tolerated. [7] [8] [9] [10] [11] [12] [13] [14] The American College of Chest Physicians (ACCP) and the International Union of Angiology (IUA) guidelines recommend VTE prophylaxis in acutely ill hospitalized medical patients with either a low-dose UFH or a LMWH. 1, 2 Furthermore, both UFH and LMWH are cost-effective when compared with no prophylaxis, if the lower morbidity and mortality associated with reducing VTE incidence and the resultant savings in hospitalization costs are taken into consideration. [15] [16] [17] Low-molecular-weight heparins have an improved pharmacokinetic profile compared with UFH, which reduces the need for frequent drug monitoring and allows for once-daily dosing. This review discusses the differences in the practical use of LMWH and UFH when used for VTE prophylaxis in acutely ill hospitalized medical patients.
Economic Rationale for Thromboprophylaxis
Venous thromboembolic complications result in a significant burden on health care services. An economic analysis based on US administrative claims data from almost 27 000 patients reported that the median annualized total reimbursed costs of an initial DVT event was US$17,512 in patients with DVT. 18 Other US economic studies have reported costs of an initial VTE event ranging from US$3131 to US$10 804 for DVT alone, and US$6678 to US$16 644 for both PE and DVT. 6, 19 These calculations can vary depending on a number of factors. For example, most studies of DVT treatment include both provoked and idiopathic DVT, while others focused on VTE prevention in hospitalized patients are based on provoked DVT only. Provoked DVTs have a different natural history than idiopathic DVT, for example, they have fewer recurrences. Therefore, the cost estimates may be higher if based on studies that include both provoked and idiopathic, compared with provoked only.
The direct medical costs associated with VTE are high owing to the costs of the initial and recurrent episodes, which include hospitalization and rehospitalization costs. The cumulative incidence of recurrent VTE has been reported to be approximately 17.5% after 2 years and 30.3% after 8 years. 20 A recent analysis of administrative claims data from 30 managed-care organizations across the United States reported that hospital readmission rates within 1 year for VTE were 5% to 14%, the majority of which occurred within 90 days of the index episode. 6 These authors also documented a 21% increase in the cost of treating recurrent VTE compared with the initial episode, mainly due to the increased length of hospital stay required. Hospital readmission costs were estimated at US$11 862 for a recurrent DVT and US$14 722 for recurrent PE. 6 Another analysis based on 2 large US health care plans reported a VTE recurrence rate of 13.4%, after a median follow-up of 19.2 months. Furthermore, the median cost of bleeding complications requiring hospitalization was estimated at US$5736 per recurrent VTE. 19 Patients who sustain an initial VTE event are also at significant risk of developing long-term complications, such as postthrombotic syndrome (PTS). The symptoms of PTS include chronic swelling and discomfort of the lower extremities and ulceration due to venous insufficiency. In one study, PTS developed in 43.3% of patients after a mean + standard deviation (SD) of 44 + 23 months. 21 Proximal (not distal) DVT was the strongest predictor of PTS (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.3-3.7). They also found that PTS was associated with a higher rate of recurrent VTE at 4 years (7.4%; 95% CI, 3.2-11.7) compared with no PTS (1.6%; 95% CI 0.0-3.5; P < .02). 21 Furthermore, as demonstrated in the study by Prandoni and colleagues, the incidence of PTS increases with time, with a 22.8% incidence after 2 years, 28.0% after 5 years, and 29.1% after 8 years. 20 Several studies have evaluated the health care costs of PTS. A literature-based model from the United States estimated that the total additional cost for treating PTS 15 years following a primary DVT was approximately US$3000. Postthrombotic syndrome contributed 74% to 81% of the total cost of treating DVT. 22 A small study from Brazil, based on patients diagnosed with PTS or with a documented history of DVT (confirmed objectively by duplex scan or venography), documented a mean annual cost per patient of approximately US$400 for mild-to-moderate PTS and US$1200 for severe PTS; the cost difference was due to higher hospitalization costs in patients with severe PTS. 23 In cases of severe PTS, the chronic leg pain and swelling may be so incapacitating that further socioeconomic costs, in terms of lost wages, incapacity benefits, and health insurance claims, also need to be taken into account.
The prevalence and costs of recurrent VTE and the potential for long-term complications from the condition highlight the importance of effective primary and secondary thromboprophylaxis in these at-risk medical patients.
Efficacy and Safety of Heparin Thromboprophylaxis in Medical Patients

General Medical Population
Studies among acutely ill general medical populations have demonstrated the efficacy and safety of both UFH and LMWH prophylaxis compared with placebo. In these studies, the relative risk (RR) of objectively determined DVT in hospitalized medical patients was reduced by up to 70% with heparinbased prophylaxis, without significantly increasing the risk of bleeding complications compared with placebo or no prophylaxis. [7] [8] [9] [10] [11] [12] A number of ''head-to-head'' trials 13, [24] [25] [26] [27] and a meta-analysis 28 have compared prophylaxis with UFH and LMWHs in hospitalized medical patients. However, it should be noted that, as the clinical end points, methodology, and patient populations vary between studies, the outcomes and therefore conclusions of each study are likely to differ. Here we present the findings and conclusions from each study. In the majority of these studies, LMWH demonstrated comparable efficacy to UFH in reducing VTE events, without increasing bleeding complications. 13, [24] [25] [26] A meta-analysis of studies of thromboprophylaxis in hospitalized medical patients observed a significant reduction in the risk of DVT and PE (56% and 58%, respectively), using either UFH or LMWH. 14 Although the efficacy of UFH and LMWH are similar, Mismetti and colleagues 14 found that LMWH prophylaxis reduced the risk of major hemorrhage by 52% compared with UFH (P ¼ .049). However, a more recent analysis of pooled safety data from the Prophylaxis in Medical Patients with Enoxaparin (MEDENOX), 11 the Thromboembolism-Prevention in Cardiac or Respiratory Disease with Enoxaparin (THE-PRINCE), 13 and Thromboembolism Prophylaxis in Internal Medicine with Enoxaparin (THE PRIME) 26 studies reported similar major bleeding rates of about 1% among enoxaparin-, UFH-, or placebo-treated patients (P ¼ 1.0 for UFH vs placebo; P ¼ .5 for enoxaparin vs placebo; P ¼ .8 for UFH vs enoxaparin). 29 Nevertheless, this analysis reported that the incidence of minor bleeding complications was significantly higher in the UFHtreated patients than in the enoxaparin groups (RR, 1.7; 95% CI, 1.3-2.2; P ¼ .0001). 29 A recent meta-analysis, which included 36 trials investigating the use of prophylaxis in medical patients, revealed that LMWH was associated with a lower risk of DVT (RR, 0.68; 95% CI, 0.52-0.88) and injection site hematoma (RR, 0.47; 95% CI, 0.36-0.62) compared with UFH. 30 In summary, these studies demonstrate that thromboprophylaxis with LMWH is associated with a similar or lower rate of VTE compared with UFH, and similar or lower rates of bleeding complications.
High-Risk Medical Patients
Low-molecular-weight heparin prophylaxis also significantly reduces the risk of VTE in high-risk subgroups of medical patients, such as those with congestive heart failure, 13, 31 severe respiratory disease, 13, 31 acute infectious illnesses, 31 and ischemic stroke, 32, 33 and is well tolerated.
One meta-analysis of clinical trials comparing enoxaparin 40 mg once daily with UFH 5000 IU either 2 or 3 times daily in acutely ill medical patients revealed a 38% reduction in VTE favoring enoxaparin, a nonsignificant reduction in death (16%), and no significant increase in major bleeding. 34 Low-molecularweight heparin prophylaxis also reduces the risk of VTE in elderly patients (aged >75 years) and those who are obese. In elderly patients, the primary end point of symptomatic VTE, fatal PE, sudden death, or asymptomatic proximal DVT at day 21 was reported in 4.2% of patients receiving prophylaxis and 8.0% of patients given placebo. For obese patients, the rates were 2.8% and 4.3%, respectively. 35 Recently, the results of the Prevention of VTE After Acute Ischemic Stroke with Low-molecularweight Heparin Enoxaparin (PREVAIL) trial showed that, in patients recovering from acute ischemic stroke, enoxaparin (40 mg once daily) reduced the risk of VTE by 43%, compared with UFH 5000 IU twice daily (RR, 0.57; 95% CI, 0.44-0.76; P ¼ .0001). 27 This reduction was consistent for patients regardless of whether they had a National Institutes of Health Stroke Scale score of 14 or more, or less than 14. There was also a 53% reduction in proximal DVT rates. There was no difference in the overall rate of any bleeding complications between treatment groups (8% in each group). 27 In a meta-analysis of 3 studies comparing UFH and LMWH following ischemic stroke in 2028 patients, treatment with LMWH conferred a significant risk reduction of any VTE event (OR, 0.54; 95% CI, 0.41-0.70; P < .001. 28 Risk benefits for LMWH over UFH were also seen when the analysis was limited to proximal VTE events (OR, 0.53; 95% CI, 0.37-0.75; P < .001) and PE (OR, 0.26; 95% CI, 0.07-0.95; P ¼ .042). 28 In this meta-analysis, there were no differences in the rates of overall bleeding, intracranial hemorrhage, or mortality with LMWH compared with UFH. 28 A subsequent Cochrane review including 9 clinical trials and 3137 patients investigated the effect of VTE prophylaxis with LMWH or heparinoids compared with standard UFH (2 or 3 times daily) for acute ischemic stroke. 36 In this review, LMWH or heparinoids were associated with a significant reduction in the odds of DVT compared with standard UFH (OR, 0.55; 95% CI, 0.44-0.70). This trend also held true when the heparinoid (OR, 0.52; 95% CI, 0.31-0.86; P ¼ .01) or LMWH (OR, 0.56; 95% CI, 0.44-0.73; P < .00001), both compared with UFH, were analyzed separately. There was no difference in minor bleeding between patients receiving LMWH or heparinoid compared with those receiving UFH (OR, 0.91; 95% CI, 0.67-1.24). As most patients at high risk of major bleeding would have been excluded from trials, there was a very low absolute risk of major bleeding and so the comparison between treatment groups was not feasible. 36 Both the ACCP and the IUA recommend prophylaxis with either low-dose UFH or LMWH in acutely ill medical patients hospitalized with congestive heart failure, severe respiratory disease, or those who are confined to bed and have one or more VTE risk factor. 1, 2 The use of mechanical thromboprophylaxis is recommended for medical patients when they are at risk for VTE but have contraindication to anticoagulant thromboprophylaxis. 1 It should be noted that the ACCP recommendations do not specify the dosing regimen of UFH (2 or 3 times daily). 1 However, the latest IUA guidelines published in 2006 specify a 3 times daily UFH regimen for medical patients at high risk of VTE. 2 Dose frequency has an important impact on efficacy, safety, and cost of prophylaxis.
Cost-Effectiveness of Heparin Thromboprophylaxis in Medical Patients
Prophylaxis versus no prophylaxis
To establish whether thromboprophylaxis is costeffective in medical patients, a number of analyses have investigated the cost implications of using UFH-or LMWH-based thromboprophylaxis when compared with no prophylaxis or placebo. [15] [16] [17] [37] [38] [39] [40] However, these are conducted across many different countries and the data cannot be directly compared between studies, as every country has their own health care system factors that affect the cost-effectiveness analyses, such as drug costs, pharmacy costs, as well as diagnosis-related and group-related costs. As there are only a few US-specific cost-effectiveness studies, we have included the data from trials based in other countries for completeness. However, the data from the trials based in different countries may not be directly comparable. Furthermore, the conversion from foreign currency to dollars, which is subject to much variability, may also affect the costs and cost-effectiveness data. Therefore, the objective of this section is not to compare between studies but to highlight the studies that support the cost-effectiveness of thromboprophylaxis compared with no prophylaxis.
In the studies summarized in Table 1 , the incremental cost-effectiveness ratio is used as the end point. This is defined as the ratio of the change in costs of administering thromboprophylaxis (with UFH or LMWH enoxaparin) to the change in effects of this intervention, namely the prevention of VTE. There may be some differences in the cost-effectiveness data between studies due to the variation in the definition of the primary clinical outcome. In particular, it should be noted that costs are driven by symptomatic DVT and PE, rather than asymptomatic or subclinical DVT or PE.
Many of the trials are based on the MEDENOX trial assumptions, which compared the use of enoxaparin versus placebo and assessed VTE rates on days 1 and 14, using bilateral venography or ultasonography. Using different methodologies and parameters (Table 1) , these analyses established that enoxaparin was cost-effective when compared with no thromboprophylaxis. [15] [16] [17] 37, 40 In the US subanalyses, the incremental cost-effectiveness of using enoxaparin rather than no prophylaxis ranged from US$1021 to US$2856 per VTE event avoided. 15 The authors concluded that a VTE rate of 3% to 4% in patients not receiving thromboprophylaxis was required for prophylaxis to ''breakeven'' (i.e., the costs of prophylaxis match the likely costs of treatment). 15 In Spain, acutely ill medical patients enrolled in the MEDE-NOX study, the cost per VTE event avoided was 432 euro and the cost per death averted was 1527 euro. 37 When these data were applied to a lifetime economic model, which assumed no higher risk of VTE recurrence, the use of enoxaparin was associated with a cost per event avoided of 270 euro and a cost per life-year gained of 71 euro, when compared with no prophylaxis. If the model allowed for an increased risk of VTE recurrence in asymptomatic patients, enoxaparin was still dominant over no prophylaxis. 37 A Canadian-based analysis using the MEDENOX study data reported an incremental cost-effectiveness ratio with enoxaparin prophylaxis compared with no prophylaxis of US$87 per VTE avoided. 17 Prophylaxis with enoxaparin was cost saving compared with no prophylaxis in the community hospital setting, which assumed 50% inpatient and 50% outpatient, with a total expected cost per patient of US$68 with enoxaparin and US$72 with placebo. 17 A UK study of 2000 patients selected according to the MEDENOX inclusion criteria accounted for hospital-specific costs (prophylaxis, diagnosis, and treatment of VTE, as well as major bleeding and PTS) and assumed maximum uptake of thromboprophylaxis treatment.. The efficacy outcome was the VTE (DVT and PE) rates. In this study, the cost associated with enoxaparin prophylaxis was 198,000 pounds, compared with 176,000 pounds associated with no prophylaxis. Nevertheless, enoxaparin was cost saving compared with no prophylaxis, with savings of 31,000 pounds based on maximum uptake of prophylaxis. 38 The cost-effectiveness of enoxaparin thromboprophylaxis compared with placebo was also demonstrated when the management costs of PTS were included with the costs of VTE prophylaxis, diagnosis, and treatment. 39 In a hypothetical cohort of 1000 French medical patients, a 10-day course of enoxaparin was more effective and less expensive than placebo. The primary efficacy criterion was the incremental change in mortality between the 2 treatment groups, and overall and symptomatic VTE event rates were also examined. If the costs of managing PTS complications were excluded, the median cost-effectiveness ratio in terms of cost per death avoided (enoxaparin to placebo) was 8102 euro. The costs per life-year saved were also calculated. Assuming a conservative 3-year life expectancy, the cost per life-year saved was 2701 euro. 39 Therefore, although thromboprophylaxis may be associated with higher initial costs, it is a more effective and more cost-effective option when compared with no prophylaxis. The question remaining is whether one form of thromboprophylaxis is more cost-effective than another.
LMWH versus UFH
A UK cost-effectiveness analysis of enoxaparin and UFH prophylaxis, based on a hypothetical cohort of 100 acutely ill medical patients, reported that the total cost of prophylaxis was 9992 pounds for enoxaparin (40 mg once daily) and 9972 pounds for UFH (5000 IU twice daily). 16 Enoxaparin was found to be slightly cost saving compared to UFH because it was associated with fewer adverse events. 16 A similar cost-effectiveness analysis was performed in the United States, investigating the numbers and costs of enoxaparin (40 mg once daily) and UFH (5000 IU twice daily) in a hypothetical cohort of 10 000 acutely ill medical patients (Figure 1 ). 40 This study found that the total costs of VTE prophylaxis and treatment were US$3,502,000, with enoxaparin and US$3,772,000 with UFH. Furthermore, enoxaparin remained more cost-effective, when compared with UFH, in specific populations of patients with heart failure, respiratory disease, or acute infection. 40 In a US-based study, Weinberg and colleagues retrospectively analyzed 89 584 patients at high risk for VTE, classifying patients according to the modified All-Payer, Severity-Adjusted Diagnosis-Related Groups. 41 For treatment costs, enoxaparin was associated with lower overall costs compared with UFH in 74% of cases. Cost differences between enoxaparin and UFH in equivalent groups were statistically significant in 36% of cases, 88% of which favored enoxaparin. These treatment group differences translated into statistically significant lower total costs of US$12,625 for enoxaparin and US$14,867 in patients receiving UFH (P < .001). 41 In light of the high costs associated with preventing and treating VTE and its sequelae, several factors need to be taken into consideration when comparing the cost-effectiveness of therapies. To reflect clinical practices accurately, cost-effectiveness analyses should not only consider the drug acquisition costs per treatment but also include practical factors such as the dosing frequency of UFH (2 or 3 times daily), the duration of therapy, and the likelihood and cost of VTE recurrence and long-term complications.
Practical Aspects of Thromboprophylaxis in Medical Patients
Incidence of Heparin-Induced Thrombocytopenia
Immune-mediated type II heparin-induced thrombocytopenia (HIT) is one of the most serious adverse effects associated with heparin prophylaxis, and surgery is a significant risk factor for HIT. 42 Accordingly, the incidence of HIT in surgical patients has been well characterized, 43 with many studies reporting a significant reduction in HIT with LMWH versus UFH. 44, 45 Furthermore, a meta-analysis of HIT incidence including both surgical and medical patients receiving VTE prophylaxis showed that LMWH reduces the rate of HIT by 90% compared with patients receiving UFH. 46 However, the incidence of HIT in medical-only populations is less well defined. Heparin-induced thrombocytopenia has been reported to occur in approximately 1% of medical patients receiving VTE prophylaxis with UFH. 47 There has been controversy when comparing the rates of HIT in medical patients receiving UFH or LMWH. One recent meta-analysis of patients treated for DVT and/or PE showed no statistically significant difference in the rate of heparinassociated thrombocytopenia between LMWH and UFH. 48 However, a number of prospective studies in medical patients have found a lower incidence of HIT with LMWH compared with UFH. [49] [50] [51] Furthermore, these studies were assessed in a meta-analysis by Warkentin and colleagues. 52 They found that treatment with a LMWH rather than UFH reduced the incidence of HIT in medical patients (0.53% vs 0.94%, respectively). These data are corroborated by studies in medical patients, which reported no cases of decreased platelet counts in patients treated with LMWH, 25, 26 and a retrospective analysis of over 10 000 medical patients in which LMWH was associated with a significantly reduced rate of HIT (0.084% compared with 0.51% with UFH; P ¼ .037). 53 In this study, the rates of HIT significantly contributed toward the cost of hospital admissions; the cost of admission for patients with HIT was US$56,364 versus US$15,231 in patients without (P < .001). Using LMWH to prevent VTE translated into a cost saving of US$13.88 per patient compared with using UFH. 53 In a recent US cost-effectiveness analysis of DVT prevention in medical inpatients, the routine use of LMWH resulted in net savings of US$89 per patient, despite higher acquisition costs. This was mainly due to the lower rate of HIT with LMWH ( Figure 2) , although univariate sensitivity analyses showed that the model was sensitive to the odds ratio of HIT and the cost of HIT, which were variables. 54 
Special Patient Subgroups
Low-molecular-weight heparins are predominantly eliminated through the renal system. In patients with severely impaired renal function there is a prolonged elimination half-life compared with those with normal renal function. 55 Therefore, there is a potential for drug accumulation, which may cause an increased risk of major bleeding complications. For example, in a meta-analysis of 4971 patients treated with LWMH, major bleeding occurred in 2.4% of patients with creatinine clearance (CrCl) of >30 mL/min versus 5% in those with severe renal impairment (CrCl <30 mL/min; P ¼ .013). 56 Therefore, patients with mild or moderate renal impairment given LMWH require careful observation for signs and symptoms of bleeding. Dose adjustments are currently only required in patients with severe renal impairment (see prescribing information), due to the potential for drug accumulation and bleeding risk.
Dosing of Anticoagulant
The frequency of anticoagulant dosing used for VTE prophylaxis affects both the patient and hospital resources. UFH has a relatively short half-life and is administered by subcutaneous injection either 2 or 3 times daily. Some studies of UFH prophylaxis in medical patients have used twice-daily dosing, 9, 24, 57, 58 whereas others have used 3 times daily dosing. 7, 8, 13, 25, 26 Recently, a meta-analysis of all the randomized controlled clinical trials of VTE prophylaxis with UFH in medical patients demonstrated that 3 times daily dosing was likely to prevent VTE events more effectively than a twice-daily regimen. A significant decrease in the composite end point of PE and proximal DVT was identified in patients receiving UFH 3 times daily versus 2 times daily (0.9 events vs 2.3 events per 1000 patient-days, respectively; P ¼ .05). 59 These data were also supported by a literature analysis that included 36 trials where a UFH dosage of 5000 IU 3 times daily (RR, 0.27; 95% CI, 0.20-0.36) was more effective in preventing DVT than a twice-daily regimen (RR, 0.52; 95% CI, 0.28-0.96) compared with controls. 30 However, in the study of King et al, the reduction in VTE events with 3 times daily UFH was offset by a significant increase in the rate of major bleeding complications compared with twice-daily UFH (0.96 vs 0.35 events per 1000 patient-days, respectively; P < .001). 59 The authors recommend that physicians assess patient risk on an individual basis to guide UFH dosing decisions. Current expert guidelines on VTE prevention recommend either 2 or 3 times daily dosing according to VTE risk levels. Three times daily dosing is recommended in patients at higher risk of VTE, provided they are not at an increased risk of bleeding complications. 1, 2 By contrast, LMWHs have a higher bioavailability and a longer half-life than UFH and can therefore be administered subcutaneously once daily. 60 All clinical studies of LMWHs in medical patients have used once-daily dosing. [11] [12] [13] 27 The differences in dosing frequency between UFH and LMWHs directly affect the manpower time required per dose administration, and consequently on their relative cost-effectiveness. A UK economic evaluation of UFH and LMWH in medical patients estimated that a 10-day course of prophylaxis with the LMWH enoxaparin required 10 injections, each lasting 1.13 minutes. Using a unit cost of 36.94 pounds per hour of nurse time, this equates to 6.96 pounds per patient. For UFH prophylaxis, the analysis assumed twice-daily dosing, yielding 20 injections lasting 2.14 minutes each, equating to 26.35 pounds per patient (using the same nursing unit costs). 16 A US cost-effectiveness analysis of heparin prophylaxis, which assumed twice-daily dosing of UFH, also assessed nursing costs. In this study, 5 days of prophylaxis with enoxaparin cost US$172 versus US$112 for UFH. 40 However, when the costs of managing adverse events, diagnosis, and treatment were included, enoxaparin was less costly than UFH (US$3,502,000 vs US$3,772,000, respectively). 40 The cost-effectiveness analyses discussed above assume a twice-daily dose of UFH. 16, 40 However, many patients, especially those at high risk of VTE, such as those with congestive heart failure or acute infections, receive UFH 3 times daily. This is likely to carry even higher costs of treatment, both in terms of hospital resources and in managing the higher risk of associated bleeding complications. 59 Dose frequency also contributes to patient compliance. One study showed that treatment adherence was inversely proportional to frequency of dose, based on 1 to 4 daily doses. 61 This effect may be even more pronounced when the treatment administration route is by injection. Simplifying the prophylaxis regimen by reducing either the frequency of dosing or the complexity of the dosing schedule, as is possible with a once-daily dose of a LMWH, has been shown to be 1 of the 4 key categories with which to improve patient compliance. 62 The dosing frequency may also affect the prescribing physicians' compliance to guideline recommendations. The current ACCP guidelines include recommendations regarding the appropriate type, dose, and duration of prophylaxis. However, recent studies suggest that many medical patients at risk of VTE do not receive the appropriate duration of prophylaxis. [63] [64] [65] Yu and colleagues reported that almost half of patients started prophylaxis late (did not receive prophylaxis at admission) and stopped prophylaxis early (before hospital discharge). 63 Thus, the number of daily doses may also have implications for patients and nurses, and consequently for the appropriate administration of prophylaxis.
In conclusion, the simplified once-daily dosing regimen with LMWH compared with UFH not only provides an economic advantage by saving nursing time but may also increase patient adherence to therapy. Furthermore, these characteristics also allow for LMWH to be administered in the outpatient setting, which means that patients can receive prophylaxis beyond their in-hospital stay.
Duration of Prophylaxis
Standard prophylactic regimens in medical patients typically last 5 to 14 days. However, there is good evidence that certain high-risk surgical (e.g., those with cancer) and medical patients (e.g., immobile acutely ill) may benefit from extended-duration prophylaxis. [66] [67] [68] [69] [70] The preliminary results from the Extended Clinical Prophylaxis in Acutely Ill Medical Patients (EXCLAIM) study have recently been reported in abstract form. 70 This study demonstrated that in 5049 acutely ill medical inpatients with reduced mobility, extended prophylaxis with enoxaparin (40 mg once daily) for 38 days significantly reduced the overall incidence of VTE by 44%, when compared with a standard 10-day regimen of enoxaparin. Extended-duration prophylaxis was associated with an increase in major bleeding complications compared with placebo (0.6% vs 0.1%, respectively), but the incidence of major bleeding was low overall. 70 A more detailed report on these findings is expected within a full primary publication.
There is a trend towards reducing the length of hospital stay. Although this applies mainly to surgical patients, if a medical patient is discharged prior to the end of their prophylactic therapy, outpatient prophylaxis may offer an appropriate approach to optimizing VTE prevention. As prophylaxis with UFH requires 2 to 3 injections per day, this is not a convenient outpatient therapy. However, LMWHs require only once-daily dosing, making them the preferred option in the outpatient setting. Low-molecularweight heparin prophylaxis can be self-administered by patients, administered at an outpatient clinic, or given by a nurse during a home visit; these options directly impact the cost of LMWH outpatient prophylaxis. In surgical patients, extended prophylaxis with enoxaparin has been shown to be cost-effective (versus a standard regimen of enoxaparin), provided that at least 50% of patients self-administer their prophylaxis. 71 A US economic analysis of VTE prophylaxis with enoxaparin in medical patients, which factored in costs of outpatient treatment in patients whose hospital stay was longer than 6 days found that the projected total costs ranged from US$117 (patient self-administration, lowest dispensing costs) to US$290 (administration by home nurse, highest pharmacy costs). 15 Data from studies such as MEDENOX and the Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients (PREVENT) indicate that acutely ill medical patients face a 15% to -20% risk of VTE, suggesting that LMWH prophylaxis would be a cost-effective strategy. 11, 12 A recent study in medical patients has shown that enoxaparin (40 mg once daily) is a cost-effective strategy in both the hospital and outpatient setting. 17 Lamy and colleagues have reported a Canadian economic analysis based on a tertiary hospital environment in which 90% of patients received DVT prophylaxis as outpatients; the incremental cost of enoxaparin was US$87 per VTE event avoided. 17 Given that the average outpatient DVT treatment costs were US$658 and US$646 for proximal and distal DVT, respectively, this indicates significant cost savings with enoxaparin prophylaxis.
Conclusions
Optimal, evidence-based prophylactic strategies should be implemented in all hospitalized medical patients to reduce the initial risk of VTE and decrease the rate of recurrent thrombotic events. This in turn will help prevent the long-term morbidity and mortality associated with VTE. Prophylaxis with either UFH or a LMWH has been clinically proven to effectively reduce the incidence of both asymptomatic and symptomatic VTE by at least 50% in a range of medical inpatients and is generally well tolerated. 1 Furthermore, in acutely ill medical patients, thromboprophylaxis with either UFH or LMWH is cost-effective compared with no prophylaxis. 15, 40 Current ACCP and IUA guidelines recommend either UFH or LMWH for VTE prophylaxis in medical patients at high risk of VTE complications (both Grade 1A recommendations).
LMWHs are at least as effective as low-dose UFH in preventing VTE and are associated with some practical and clinical advantages compared with UFH prophylaxis. For example, LMWHs are associated with lower incidences of bleeding complications and HIT. Furthermore, LMWHs are administered once daily and can be given more easily on an outpatient basis, thereby reducing the demand on hospital resources. The savings accrued from these practical advantages, such as reduced use of nursing time associated with once-daily dosing and a lower incidence of bleeding complications and HIT, all contribute to LMWH being a more costeffective option compared with UFH.
